Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.56 - $0.9 $11,735 - $18,861
-20,957 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$10.51 - $17.22 $220,258 - $360,879
20,957
20,957 $352,000

Others Institutions Holding GLYC

About GLYCOMIMETICS INC


  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $14.7M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track This Portfolio

Track Virtus Fund Advisers, LLC Portfolio

Follow Virtus Fund Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus Fund Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus Fund Advisers, LLC with notifications on news.